Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Tax Provisions (2022 - 2025)

Historic Tax Provisions for Gyre Therapeutics (GYRE) over the last 8 years, with Q3 2025 value amounting to $1.7 million.

  • Gyre Therapeutics' Tax Provisions rose 5763.5% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 3291.73%. This contributed to the annual value of $6.3 million for FY2024, which is 3237.78% down from last year.
  • Per Gyre Therapeutics' latest filing, its Tax Provisions stood at $1.7 million for Q3 2025, which was up 5763.5% from $662000.0 recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Tax Provisions peaked at $6.0 million during Q4 2022, and registered a low of $662000.0 during Q2 2025.
  • Over the past 4 years, Gyre Therapeutics' median Tax Provisions value was $1.6 million (recorded in 2023), while the average stood at $2.1 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first crashed by 7439.88% in 2023, then surged by 5763.5% in 2025.
  • Quarter analysis of 4 years shows Gyre Therapeutics' Tax Provisions stood at $6.0 million in 2022, then tumbled by 74.4% to $1.5 million in 2023, then fell by 21.4% to $1.2 million in 2024, then surged by 40.5% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $662000.0 for Q2 2025, and $901000.0 during Q1 2025.